Candida auris Infections in COVID-19 Patients: A Review.

ABSTRACT

An increase in the incidence of invasive fungal infection, which can lead to serious complications and death, has been detected in some patients who had Coronavirus disease-2019 (COVID-19). Since the beginning of the COVID-19 pandemic, fungal infections increase the risk of mortality in long-term hospitalized COVID-19 patients. C. auris has emerged as a multidrug-resistant fungal pathogen isolated from healthcare-associated infections globally. Studies have reported an increase in C. auris isolation in COVID-19 patients who developed candidemia. They stated that C. auris is the most isolated Candida species in blood cultures since the beginning of the SARSCoV-2 pandemic, replacing other Candida species. In the studies included in this study, the mean incidance of C. auris was found to be as 22.7% (74/325) in COVID-19 patients with suspected fungal infection. The aim of our study is to evaluate the literature published so far in Turkiye and in the world regarding the coexistence of C. auris and COVID-19, which was reported as an "immediate threat" by the Centers for Disease Control and Prevention (CDC). However, there is not enough information about the effect of C. auris coinfection on mortality and whether it is an indicator of the severity of COVID-19 infection. Well-designed and careful epidemiological studies are needed to define the true burden of invasive candidiasis in COVID-19 patients.Copyright © 2023 Bilimsel Tip Yayinevi. All rights reserved.